Tag: PropheSee
CCS platform saves more than $10M
May 14, 2025HME News Staff
DALLAS – CCS has saved more than $10 million in taxpayer dollars through the use of PropheSee, its predictive analytics platform, according to a new study.
The company identified more than 14,400 Medicare patients at risk of lapsing on their continuous glucose monitoring therapy and segmented them into defined personas based on patient-specific clinical, socioeconomic and behavioral data. It then designed and deployed customized interventions to effect lasting behavior change, leading...
CCS sees AI tool as next step in diabetes care evolution
June 21, 2024Theresa Flaherty, Managing Editor
DALLAS – The volume of data being collected from diabetes patients presents an opportunity to use artificial intelligence to better understand which patients are at risk for non-adherence to therapy, says Richard Mackey, chief technology officer at CCS, which recently launched PropheSee, an AI-powered predictive model for CGM users.
“We want to deliver insights that help them anticipate whatever needs they might have (and identify) situations where some additional support or...
In brief: CCS launches PropheSee, Vertess’ Smith recognized
June 12, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for health care organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk...
CCS Launches AI-powered model
June 11, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification,...